Rallybio (RLYB) Shares Outstanding (2020 - 2026)
Rallybio (RLYB) posted Shares Outstanding (Entity) of $5.3 million for Q1 2026, little changed sequentially from $5.3 million in Q4 2025, and up 1.71% YoY from $5.2 million in Q1 2025.
Rallybio (RLYB) Shares Outstanding (2020 - 2026) Analysis & Trends
Rallybio has reported Shares Outstanding (Entity) for 7 years, with the latest figure at $5.3 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 1.71% year-over-year to $5.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.3 million (up 1.71% YoY) and the FY2025 annual result came in at $5.3 million, up 1.82% from the prior year.
- Shares Outstanding (Entity) held at $5.3 million in Q1 2026 per RLYB's latest filing, from $5.3 million in the prior quarter.
- Over five years, Shares Outstanding (Entity) peaked at $5.3 million in Q1 2026 and troughed at $4.0 million in Q3 2022.
- A 5-year average of $4.8 million and a median of $4.7 million in 2022 frame the typical range for Shares Outstanding (Entity).
- The widest YoY moves for Shares Outstanding (Entity): up 707.71% in 2022, down 0.12% in 2022.
- Over 5 years, Shares Outstanding (Entity) stood at $4.7 million in 2022, then retreated by 0.02% to $4.7 million in 2023, then rose by 9.73% to $5.2 million in 2024, then rose by 1.82% to $5.3 million in 2025, then rose by 0.13% to $5.3 million in 2026.
- According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $5.3 million, $5.3 million, and $5.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Rallybio | 94.61 Mn | 94.61 Mn | - | 5.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.70 Mn |
| Mar 31, 2026 | 5.69 Mn |
| Dec 31, 2025 | 5.63 Mn |
| Sep 30, 2025 | 5.63 Mn |
| Jun 30, 2025 | 5.61 Mn |
| Mar 31, 2025 | 5.60 Mn |
| Dec 31, 2024 | 5.44 Mn |
| Sep 30, 2024 | 5.57 Mn |
| Jun 30, 2024 | 5.52 Mn |
| Mar 31, 2024 | 5.10 Mn |
| Dec 31, 2023 | 5.06 Mn |
| Sep 30, 2023 | 5.07 Mn |
| Jun 30, 2023 | 5.05 Mn |
| Mar 31, 2023 | 5.03 Mn |
| Dec 31, 2022 | 3.98 Mn |
| Sep 30, 2022 | 3.85 Mn |
| Jun 30, 2022 | 3.82 Mn |
| Mar 31, 2022 | 3.79 Mn |
| Dec 31, 2021 | 3.19 Mn |
| Sep 30, 2021 | 3.44 Mn |